Turkish Journal of Gastroenterology
Original Article

DR-70 as a novel diagnostic biomarker for gastric cancer


Department of Internal Medicine, Divison of Gastroenterology, Gazi University Faculty of Medicine, Ankara, Turkey


Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Turkey


Department of Medical Biochemistry, Gazi University Faculty of Medicine, Ankara, Turkey

Turk J Gastroenterol 2015; 26: 480-483
DOI: 10.5152/tjg.2015.0425
Read: 564 Downloads: 130 Published: 25 July 2019


Background/Aims: To assess the utility of the DR-70 immunoassay in the diagnosis of gastric cancer.


Materials and Methods: A total of 29 patients with histologically proven malignant gastric tumor and 29 healthy blood donors were enrolled in this study. DR-70 immunoassay was performed using an enzyme-linked immunosorbent assay kit to quantify the serum levels of fibrin degradation products.


Results: The DR-70 values in patients with gastric cancer significantly differed from the values in controls (p<0.0001). Receiver operating characteristic curve analysis revealed ≥1.45 µg/mL as the best cut-off value to distinguish between patients with gastric cancer and healthy controls. The area under the receiver operating characteristic curve was 0.871. Using ≥1.45 µg/mL as the cut-off value, the DR-70 immunoassay showed a good clinical performance with a sensitivity of 82.8% and a specificity of 79.3%. The positive predictive value was 80.0%, and the negative predictive value was 82.1%.


Conclusion: The DR-70 immunoassay reliably differs between gastric cancer and healthy controls, promising to become a useful cancer detection tool in clinical practice.

EISSN 2148-5607